Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence

Abstract excerpt

Diverse pathways drive resistance to BRAF/MEK inhibitors in BRAF-mutant melanoma, suggesting that durable control of resistance will be a challenge. By combining statistical modeling of genomic data from matched pre-treatment and post-relapse patient tumors with functional interrogation of >20 in vitro and in vivo resistance models, we discovered that major pathways of resistance converge to activate the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Melanoma and MAPK Pathways
• Share to Multiple Myeloma Research and Treatments
• Share to Protein Degradation and Inhibitors